
Results
8
Companies which are more than 50% undervalued based on analyst price target.
8 companies
Caliway Biopharmaceuticals
Market Cap: NT$158.7b
Engages in the development of drugs for aesthetic medicine and chronic inflammation.
6919
NT$102.00
7D
1.5%
1Y
-17.4%
Bora Pharmaceuticals
Market Cap: NT$48.1b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$384.50
7D
-4.1%
1Y
-43.9%
Lotus Pharmaceutical
Market Cap: NT$46.1b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$173.50
7D
-8.0%
1Y
-20.4%
Oneness Biotech
Market Cap: NT$20.3b
Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan.
4743
NT$41.20
7D
-14.0%
1Y
-35.2%
TaiMed Biologics
Market Cap: NT$15.4b
A biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases.
4147
NT$56.50
7D
-4.2%
1Y
-30.9%
Medigen Vaccine Biologics
Market Cap: NT$15.0b
A biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.
6547
NT$45.50
7D
-2.8%
1Y
5.4%
EirGenix
Market Cap: NT$13.9b
Operates as a contract development and manufacturing company in Taiwan and internationally.
6589
NT$45.30
7D
-0.7%
1Y
-29.2%
Foresee Pharmaceuticals
Market Cap: NT$12.4b
Operates as biopharmaceutical company in the United States, China, and Europe.
6576
NT$78.60
7D
-5.3%
1Y
7.1%